Pharmacological targeting of the pseudokinase Her3
- Pharmacological targeting of the pseudokinase Her3
- Ting Xie; Sang Min Lim; Kenneth D. Westover; Michael E. Dodge; Dalia Ercan; Scott B. Ficarro; Durga Udayakumar; Deepak Gurbani; Hyun Seop Tae; Steven M. Riddle; 심태보; Jarrod A. Marto; Pasi A. Janne; Craig M. Crews; Nathanael S. Gray
- Issue Date
- Nature chemical biology
- VOL 10, 1006-1012
- Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and -60 other pseudokinases found in human cells.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.